Healthy subjects.
Conditions
Interventions
Intervention 1: Oral administration of placebo. Intervention 2: Oral administration of 2.5 mg oxybutynin. Intervention 3: Oral administration of 5 mg oxybutynin. Intervention 4: Oral administration of
Placebo
Treatment - Drugs
Oral administration of 2.5 mg oxybutynin
Oral administration of 5 mg oxybutynin
Oral administration of 10 mg oxybutynin
Sponsors
Deputy for Research, Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
19 Years to 24 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: male; ages between 19-24 years old. Exclusion criteria: chronic disease (i.e. diabetes mellitus, hypertension, epilepsy and etc); smoker; under regular medication .
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean of RR interval. Timepoint: before and after administration of placebo or drug. Method of measurement: Time domain analysis of ECG.;Standard deviation of RR interval. Timepoint: before and after administration of placebo or drug. Method of measurement: Time domain analysis of ECG. | — |
Secondary
| Measure | Time frame |
|---|---|
| High frequency power spectrum. Timepoint: before ad after administration of placebo or drug. Method of measurement: Frequency domain analysis of ECG.;Low frequency power spectrum. Timepoint: before ad after administration of placebo or drug. Method of measurement: Frequency domain analysis of ECG. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed